Bide Pharmatech Co., Ltd. (SHA:688073)
China · Delayed Price · Currency is CNY 53.28
-1.21 (-2.22%)
At close: Mar 20, 2026
Bide Pharmatech Revenue
In the year 2025, Bide Pharmatech had annual revenue of 1.32B CNY with 20.13% growth. Bide Pharmatech had revenue of 344.70M in the quarter ending December 31, 2025, with 18.60% growth.
Revenue
1.32B
Revenue Growth
+20.13%
P/S Ratio
3.55
Revenue / Employee
1.79M
Employees
129
Market Cap
4.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.32B | 221.80M | 20.13% |
| Dec 31, 2024 | 1.10B | 10.15M | 0.93% |
| Dec 31, 2023 | 1.09B | 258.03M | 30.94% |
| Dec 31, 2022 | 833.83M | 227.61M | 37.55% |
| Dec 31, 2021 | 606.22M | 214.75M | 54.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.18B |
| Jinling Pharmaceutical Company | 3.13B |
| Tianjin Tianyao Pharmaceuticals | 2.87B |
| Jinhe Biotechnology CO., LTD. | 2.75B |
| Yabao Pharmaceutical Group | 2.27B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.74B |
| Tibet Weixinkang Medicine | 1.17B |
| LanZhou Foci Pharmaceutical | 895.75M |